PO-02-157 IMPACT OF ATRIAL FIBRILLATION ON QUALITY OF LIFE IN HYPERTROPHIC CARDIOMYOPATHY

In hypertrophic cardiomyopathy (HCM) atrial fibrillation (AF) has been historically described as unrelenting, a driver for heart failure, with decisive impact on quality of life. AF treatment deemed less effective in HCM due to high rates recurrence. However, predominantly characterized from physicians perspective and there is no data patient reported outcome measures (PROMs). To evaluate the PROMs HCM. were collected using Atrial Fibrillation Severity Scale (AFSS) Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) reflecting symptom burden life 250 consecutive patients. Among patients, 51 (20%) diagnosed at 56±10 years age, 6.5±5.5 prior evaluation health status. At evaluation, 45 patients (88%) sinus rhythm, 6 (12%) including 5 permanent AF. Each required symptoms: 27 (53%) solely medications (17 AV nodal 10 antiarrhythmic drugs); 24 (47%) ablation (16 catheter 8 surgical Cox-Maze IV time myectomy). Of 15 (63%) had recurrent (25%) requiring multiple procedures. After most recent ablation, was infrequent ≤1 episode per month 17 (71%), episode/year. 75% AFSS score consistent mild symptoms, 91% KCCQ-OS or disability. There difference either without recurrence after (p=0.68). The treated each episodes current therapy, but (56%) 11 With treatment, 67% symptoms 82% compared 199 (p=0.2). Recurrent common despite however tend be infrequent. majority have burden. These support that metrics are not significantly impaired